# Freenome, Inc.

**FRNM**

Nasdaq; healthcare; SIC 8071, Services-Medical Laboratories; CIK 0002017526

# None

**No letter**

4 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $92.8M |
| **Warnings** | thin data<br>not computable: degenerate inputs, distress, fortress balance sheet |
| **Inputs computable** | 4 of 14 |
| **Graded from** | filings received through Mar 12, 2026<br>246 days before the rescan; latest periodic filing 10-Q received Nov 12, 2026 |
| **Last close** | $10.63<br>2026-11-12; market equity $1.2B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 12, 2026*

We are a blank check company incorporated on March 22, 2024 as a Cayman Islands exempted company formed for the purpose of effecting a business combination with one or more businesses, which we refer to throughout this Annual Report as our initial business combination. To date, our efforts have been limited to organizational activities, as activities related to our Initial Public Offering, and since our Initial Public Offering, the search for a prospective business combination. We have generated no operating revenues to date and we do not expect that we will generate operating revenues until we consummate our initial business combination.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 84.1** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | | |
| Accruals ratio | 1.9% | (6.6%) | 84.1 | 800 | 2025-12-31 | |
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 0* | | | | | | |
| **Solvency, sleeve percentile 69.3** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *liabilities and a nearby cover-page share count are required at 2026-03-31* | | | | | | |
| Altman Z double-prime | (1.36) | (0.35) | 42.8 | 744 | 2025-12-31 | |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Current ratio | 0.40x | 2.95x | 95.8 | 826 | 2025-12-31 | |
| **Growth and financing, sleeve percentile 12.2** | | | | | | |
| Revenue growth, three-year compound | not computable | 10.1% | | | | |
| *four annual observations are required; found 0* | | | | | | |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | | |
| *four consecutive annual FCF observations are required; found 0* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Asset growth, three years | not computable | 2.2% | | | | |
| *four annual observations are required; found 2* | | | | | | |
| Net share issuance, one year | 0.0% | 2.5% | 12.2 | 627 | 2026-03-10 | |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 4 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-12 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 47.2% | (1.9%) | 77 |
| Distance from 52-week high | (38.0%) | (30.8%) | 42 |
| EBIT to enterprise value | not computable | (1.9%) | |
| Free cash flow yield | not computable | (1.0%) | |
| Book value to price | 0.41 | 0.28 | 62 |
| Sales to price | not computable | 0.29 | |
| Composite equity issuance, five years | not computable | 20.5% | |
| Relative strength against the sector, log excess return | 0.22 | (0.19) | 77 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | pass |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | fail |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | pass |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $180.4M |
| Operating cash flow, four quarters | $82.1M |
| Months of runway | not finite |
| Days since last periodic filing | 1 (10-Q received Nov 12, 2026) |
| Median daily dollar volume, 63 sessions | $9.3M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | $837,468 | 2025-12-31 | 2026-03-12 | 10-K | 26-009262 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$864,653 | 2025-12-31 | 2026-03-12 | 10-K | 26-009262 |
| 3 | assets | us-gaap:Assets | $92.8M | 2025-12-31 | 2026-03-12 | 10-K | 26-009262 |
| 4 | assets | us-gaap:Assets | $89.9M | 2024-12-31 | 2026-03-12 | 10-K | 26-009262 |
| 5 | current assets | us-gaap:AssetsCurrent | $907,570 | 2025-12-31 | 2026-03-12 | 10-K | 26-009262 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $2.3M | 2025-12-31 | 2026-03-12 | 10-K | 26-009262 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$4.8M | 2025-12-31 | 2026-03-12 | 10-K | 26-009262 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$3.0M | 2025-12-31 | 2026-03-12 | 10-K | 26-009262 |
| 9 | book equity | us-gaap:StockholdersEquity | -$4.8M | 2025-12-31 | 2026-03-12 | 10-K | 26-009262 |
| 10 | liabilities | us-gaap:Liabilities | $5.7M | 2025-12-31 | 2026-03-12 | 10-K | 26-009262 |
| 11 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 8,911,250 | 2026-03-10 | 2026-03-12 | 10-K | 26-009262 |
| 12 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 8,911,250 | 2025-03-14 | 2025-03-19 | 10-K | 25-009447 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.